Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Federal Trade Commission has filed an amicus curiae brief in a case being heard in a U.S. appellate court involving an ...

The stock's fall snapped a four-day winning streak.

Gilead Sciences has come from nowhere to dominate lists of the drugmakers with the best reputations in Asia, claiming the top ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $83.99 which represents a slight increase of $0.05 or 0.06% from the prior close of $83.94. The stock opened at $84.25 and ...

Foster City, California-based Gilead Sciences, Inc. is recalling one lot of Veklury (remdesivir) for Injection 100 mg/vial for ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer c ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...